-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED ANNOUNCES ORPATHYS® PLUS TAGRISSO® DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PROGRESSION-FREE AND OVERALL SURVIVAL IN MET-DRIVEN EGFR-MUTATED LUNG CANCER AFTER PROGRESSION ON TAGRISSO®

Reuters·08/17/2026 00:00:01

Please log in to view news